BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 9.0% in March

BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 5,590,000 shares, an increase of 9.0% from the March 15th total of 5,130,000 shares. Based on an average daily trading volume, of 511,500 shares, the short-interest ratio is currently 10.9 days.

BioAtla Price Performance

Shares of BCAB traded down $0.27 during midday trading on Monday, reaching $2.86. 598,121 shares of the stock were exchanged, compared to its average volume of 502,031. The business's 50-day moving average price is $2.83 and its 200 day moving average price is $2.21. BioAtla has a twelve month low of $1.24 and a twelve month high of $4.07. The company has a market capitalization of $137.57 million, a price-to-earnings ratio of -1.09 and a beta of 1.07.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BCAB. JMP Securities restated a "market outperform" rating and issued a $12.00 price target on shares of BioAtla in a research note on Thursday, March 28th. HC Wainwright cut their price target on BioAtla from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, March 27th.

Institutional Trading of BioAtla

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. PVG Asset Management Corp acquired a new stake in shares of BioAtla during the fourth quarter worth about $161,000. Perceptive Advisors LLC purchased a new position in shares of BioAtla during the fourth quarter worth about $180,000. Wexford Capital LP purchased a new position in shares of BioAtla during the fourth quarter worth about $29,000. Barclays PLC grew its holdings in shares of BioAtla by 666.6% during the fourth quarter. Barclays PLC now owns 60,893 shares of the company's stock worth $149,000 after buying an additional 52,950 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of BioAtla by 3.5% during the fourth quarter. Nuveen Asset Management LLC now owns 177,852 shares of the company's stock worth $438,000 after buying an additional 5,987 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company's stock.

BioAtla Company Profile

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.